Reverse translation of failed treatments can help improving the validity of preclinical animal models.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Pharmacology

• Publication date

  2015-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2015.03.030PMID 25823810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

  2014cited by this paper
• Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.

  2014cited by this paper
• The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis

  2013cited by this paper
• The Janus Head of T Cell Aging – Autoimmunity and Immunodeficiency

  2013cited by this paper
• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  2013cited by this paper
• Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis

  2013cited by this paper
• Into the valley of death: research to innovation.

  2013cited by this paper
• The Different Clinical Effects of Anti-BLyS, Anti-APRIL and Anti-CD20 Antibodies Point at a Critical Pathogenic Role of γ-Herpesvirus Infected B Cells in the Marmoset EAE Model

  2013cited by this paper
• Understanding immunosenescence to improve responses to vaccines

  2013cited by this paper
• Modelling Genetic Susceptibility to Multiple Sclerosis with Family Data

  2012cited by this paper
• Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys

  2012cited by this paper
• Unravelling the T‐cell‐mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34–56 peptide in incomplete adjuvant

  2012cited by this paper
• Treatment of multiple sclerosis with anti-CD20 antibodies.

  2012cited by this paper
• EAE: imperfect but useful models of multiple sclerosis.

  2011cited by this paper
• Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination

  2011cited by this paper
• B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis

  2011cited by this paper
• Animal models of multiple sclerosis—Potentials and limitations

  2010cited by this paper
• Late B Cell Depletion with a Human Anti-Human CD20 IgG1κ Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets

  2010cited by this paper
• Induction of Progressive Demyelinating Autoimmune Encephalomyelitis in Common Marmoset Monkeys Using MOG34-56 Peptide in Incomplete Freund Adjuvant

  2010cited by this paper
• Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

  2010cited by this paper
• A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease

  2010cited by this paper
• Surrogate approaches in development of monoclonal antibodies.

  2009cited by this paper
• Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

  2008cited by this paper
• Failure is an option: learning from unsuccessful proof-of-concept trials.

  2008cited by this paper
• Multiple sclerosis

  2008cited by this paper
• Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

  2008cited by this paper
• A prescription for human immunology.

  2008cited by this paper
• A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.

  2006cited by this paper
• Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

  2006cited by this paper
• Suppression of Ongoing Disease in a Nonhuman Primate Model of Multiple Sclerosis by a Human-Anti-Human IL-12p40 Antibody1

  2005cited by this paper
• Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice.

  2005cited by this paper
• Immunotherapy: Bewitched, Bothered, and Bewildered No More

  2004cited by this paper
• The CD4–Th1 model for multiple sclerosis: a crucial re-appraisal

  2004cited by this paper
• The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal.

  2004cited by this paper
• Of Mice and Not Men: Differences between Mouse and Human Immunology

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines

  2004cited by this paper
• Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.

  2004cited by this paper
• Twin concordance and sibling recurrence rates in multiple sclerosis

  2003cited by this paper
• Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody1

  2002cited by this paper
• Valley of Death

  2002cited by this paper
• An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin.

  2001cited by this paper
• Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction

  2000cited by this paper
• Regression and spreading of self-recognition during the development of autoimmune demyelinating disease.

  1999cited by this paper
• Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

  1997cited by this paper
• Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

  1996cited by this paper
• Evolution of Major Histocompatibility Complex Polymorphisms and T‐Cell Receptor Diversity in Primates

  1995cited by this paper
• Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease.

  1993cited by this paper
• Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies.

  1993cited by this paper
• Anti—tumor necrosis factor therapy abrogates autoimmune demyelination

  1991cited by this paper

• Utility of Animal Models of Pneumonia and Sepsis.

  2025cites this paper
• Reverse Translation

  2025cites this paper
• Reliability of common mouse behavioural tests of anxiety: A systematic review and meta-analysis on the effects of anxiolytics.

  2022cites this paper
• Biodegradable interbody cages for lumbar spine fusion: Current concepts and future directions.

  2022cites this paper
• Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?

  2022cites this paper
• Tissue Lipidomic Alterations Induced by Prolonged Dexamethasone Treatment.

  2021cites this paper
• Electrophysiological Measurements for Brain Network Characterization in Rodents

  2021cites this paper
• Animal models of Chagas disease and their translational value to drug development

  2020cites this paper
• Porcine cancer models: potential tools to enhance cancer drug trials

  2020cites this paper
• Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis

  2019cites this paper
• Bridging the species gap in translational research for neurodevelopmental disorders.

  2019cites this paper
• Advances in nonhuman primate models of autism: Integrating neuroscience and behavior.

  2018cites this paper
• Experimental Models of Autoimmune Demyelinating Diseases in Nonhuman Primates

  2018cites this paper
• Translational Aspects in Drug Discovery

  2017cites this paper